Day: August 9, 2024
Precision BioSciences Announces Investigational New Drug Clearance by Partner TG Therapeutics for Investigation of Azer-Cel for Multiple Sclerosis
- Out licensed allogeneic CAR T azer-cel receives IND clearance from U.S. FDA DURHAM, N.C. --(BUSINESS WIRE)--Aug. 9, 2024-- Precision BioSciences, Inc. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for